Drug Profile
Brimonidine tartrate - Ocugen
Alternative Names: Brimonidine nanoemulsion - Ocugen; OCU 300Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator University of Illinois at Chicago
- Developer Ocugen
- Class Antiglaucomas; Antihypertensives; Bromobenzenes; Diamines; Eye disorder therapies; Imidazoles; Quinoxalines; Skin disorder therapies; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dry eyes; Graft-versus-host disease
Most Recent Events
- 10 Mar 2021 Discontinued - Phase-II for Dry eyes (Combination therapy) in USA (Ophthalmic) before March 2021 (Ocugen's pipeline, March 2021)
- 10 Mar 2021 Discontinued - Phase-II for Dry eyes (Monotherapy) in USA (Ophthalmic) before March 2021 (Ocugen's pipeline, March 2021)
- 10 Mar 2021 Discontinued - Phase-III for Graft-versus-host disease in USA (Ophthalmic) before March 2021 (Ocugen's pipeline, March 2021)